Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: Adalimumab
DATE: 13/04/2018
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
